INTRODUCTION {#s1}
============

Cytogenetically normal AML (CN-AML) is the most commonly encountered primary AML, yet their clinical prognosis are sharply heterogeneous and it lacks effective prognostic indicators \[[@R1]\]. Although the leukemic blasts of CN-AML patients do not contain detectable chromosome abnormalities by microscope, they still harbour mutations and aberrantly expressed genes, microRNAs and changes in DNA methylation that are potential prognostic markers \[[@R2]-[@R4]\]. For example, mutations in *NPM1* \[[@R5]\] and *CEBPA* \[[@R6]\] are associated with favourable outcomes; whereas mutations in *FLT3-ITD*\[[@R7]\], *WT1* \[[@R8]\], *ASXL1* \[[@R9]\], *MLL* \[[@R10]\], *RUNX1* \[[@R11]\], *TET2* \[[@R12]\] and *DNMT3A* \[[@R13]\] are associated with an unfavourable prognosis. High expression levels of *WT1* \[[@R14]\], *BAALC* \[[@R15]\], *ERG* \[[@R16]\], *MN1* \[[@R17]\], *DNMT3B* \[[@R18]\], and *TCF4* \[[@R19]\] as well as low expression of *LEF1* \[[@R20]\] have also been shown to be unfavourable prognostic factors, as has the high expression of *miR-155* \[[@R21]\] and *miR-3151* \[[@R15]\], and low expression of *miR-181a* \[[@R22], [@R23]\].

The *NF-κB* signalling pathway plays an important role in solid tumors and hematologic malignancies, including CN-AML \[[@R24]-[@R26]\]. Recent findings suggested that *MAPKBP1* acted as a scaffold protein interacting with TNF-receptor associated factor 2 (*TRAF2*) and TGF-β-activated kinase1 (*TAK1*). *MAPKBP1* could facilitate the polyubiquitination of *TRAF2*, leading to the TAK1 mediated activation of *NF-κB* \[[@R27], [@R28]\]. According to the role of *NF-κB* in the pathogenesis of CN-AML, it was speculated that the expression of *MAPKBP1* might be related to prognosis in patients with CN-AML.

We found not only *MAPKBP1* was highly expressed in CN-AML compared to normal bone marrow (BM) when measured using microarray, but also *MAPKBP1*^high^ was an unfavourably prognostic factor in patients with CN-AML amongst 2 independent, large AML patient cohorts. In addition, the first evidence showed that expression of *MAPKBP1* was associated with distinct molecular and clinical characteristics. In order to further elucidate its function, we also identified *MAPKBP1* associated genes in the genome wide scale, as well as changes in microRNA expression and DNA methylation profiles.

RESULTS {#s2}
=======

Expression of *MAPKBP1* in CN-AML cells and normal BM {#s2_1}
-----------------------------------------------------

We analysed *MAPKBP1* expression in CN-AML and normal BM using a microarray assay. Both CN-AML (n = 116) and normal BM (n = 5) expressed *MAPKBP1*, although there was a relatively higher expression of *MAPKBP1* in the former (*P* = 0.03) (GEO accession number *GSE1159*) \[[@R29]\]. These findings indicated that *MAPKBP1* was widely expressed at a high level in CN-AML, and easy to detect. (Figure [1A and 1B](#F1){ref-type="fig"}).

![Expression of *MAPKBP1* in CN-AML patients and normal bone marrow\
Relative expression of *MAPKBP1* in 116 CN-AML cases compared with 5 normal bone marrow samples.](oncotarget-06-8144-g001){#F1}

Association of *MAPKBP1* expression levels with pre-treatment patient characteristics {#s2_2}
-------------------------------------------------------------------------------------

In the cohort of 157 CN-AML patients, patients with M1 disease were more likely to have *MAPKBP1*^high^ in the FAB subtype (*P* = 0.05). *MAPKBP1*^high^ patients were more likely to carry a *FLT-ITD* mutation (*P* \< 0.001) than *MAPKBP1*^low^ patients. We found no association between *MAPKBP1* expression and other gene mutations, but *MAPKBP1*^high^ patients with CN-AML were more likely to have a high expression of *ERG1*, *WT1*, *DNMT3B* and *TCF4* (*P* \< 0.001, *P* \< 0.001, *P* \< 0.001, and *P* \< 0.001, respectively). In addition, there was also a significant difference between the occurrence of the ELN genetic favourable group in the *MAPKBP1*^high^ and *MAPKBP1*^low^ groups (*P* = 0.001). (Table [1](#T1){ref-type="table"}).

###### Patients\' characteristics in the CN-AML cohort according to the *MAPKBP1* expression

  Variable                *MAPKBP1*^high^, n=78   *MAPKBP1*^low^, n=79   P
  ----------------------- ----------------------- ---------------------- ---------
  Median age. y (range)   48.50 (18-77)           51 (16-73)             0.256
  Female sex, no.(%)      37 (47.4)               36 (45.6)              0.87
  FAB subtype, no.                                                       
  M0                      1                       2                      1
  M1                      28                      17                     0.05
  M2                      19                      13                     0.24
  M3                      1                       0                      0.50
  M4                      13                      11                     0.66
  M5                      14                      25                     0.06
  M6                      0                       1                      1
  Other                   2                       10                     0.03
  FLT3-ITD, no.           50                      16                     \<0.001
  FLT3-TKD, no.           10                      10                     1
  NPM1, no.               46                      36                     0.11
  CEBPA, mutated, no.                                                    
  Single                  4                       4                      1
  Double                  5                       11                     0.18
  N-RAS, mutated, no.     4                       9                      0.25
  K-RAS, mutated, no.     0                       1                      1
  IDH1, mutated, no.      10                      9                      0.81
  IDH2, mutated, no.      5                       8                      0.81
  ELN genetic group, no                                                  
  Favorable               19                      40                     0.001
  Intermediate-I          68                      54                     0.19
  High ERG, no.           51                      27                     \<0.001
  High BAALC, no.         44                      34                     0.11
  High LEF1, no.          33                      45                     0.35
  High MN1, no.           42                      36                     0.34
  High WT1, no.           54                      24                     \<0.001
  High DNMT3B, no.        55                      23                     \<0.001
  High TCF4, no.          54                      24                     \<0.001

CN-AML indicates cytogenetically normal acute myeloid leukemia; FAB, French-American-British classification; ITD, internal tandem duplication; ELN, European Leukemia Net; and TKD, tyrosine kinase domain.

High *ERG, BAALC, LEF1, MN1, WT1, DNMT3B* and *TCF4* expression were defined as an expression level above the median of all samples, respectively.

*MAPKBP1*^high^ is associated with unfavourable treatment {#s2_3}
---------------------------------------------------------

As a whole, the median OS and EFS for *MAPKBP1*^high^ group were significantly shorter than that of *MAPKBP1*^low^ patients. (*P* = 0.007, *P* = 0.004, respectively. See Table [2](#T2){ref-type="table"}). While for the comparison of Log-rank test in different divisions according to *MAPKBP1* expression, *MAPKBP1*^high^ group also had significantly shorter EFS (Figure [2A](#F2){ref-type="fig"}, *P* = 0.0004) and OS (Figure [2B](#F2){ref-type="fig"}, *P* = 0.0006) compared to the *MAPKBP1*^low^ group. (Table [2](#T2){ref-type="table"}).

###### Survival according to *MAPKBP1* expression in all patients and European Leukemia Net Genetic Groups

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Outcome                             All patients, n=157                  ELN Favorable group   Intermediate-I                                                         
  ----------------------------------- --------------------- -------------- --------------------- ------------------ -------------- ------ -------------- -------------- -------
  OS                                                                                                                                                                    

   Median OS, m                       10.46\                43.47\         0.00\                 20.01\             52.28\         0.2\   8.49\          39.54\         0.04
                                      (0.07-198.7)          (0.13-214.5)   7                     (1.05-163.10)      (0.3-214.5)    7      (0.07-198.7)   (0.13-190.3)   

   Estimated OS at 3 y. % (95% CI)    0.29\                 0.58\          0.01                  0.42 (0.25-0.71)   0.63\          0.1\   0.264\         0.56\          0.04
                                      (0.21-0.42)           (0.48-0.70)                                             (0.49-0.80)    9      (0.18-0.4)     (0.44-0.71)    

  EFS                                                                                                                                                                   

   Median EFS, m                      7.64\                 28.12\         0.00\                 11.93\             40.48\         0.2\   6.83\          24.94\         0.00\
                                      (0.03-198.7)          (0.03-214.5)   4                     (0.03-131.9)       (0.03-214.5)   1      (0.03-198.7)   (0.03-190.3)   9

   Estimated EFS at 3 y. % (95% CI)   0.23\                 0.46\          0.00\                 0.37 (0.20-0.66)   0.55\          0.0\   0.19\          0.41\          0.00\
                                      (0.15-0.35)           (0.36-0.58)    2                                        (0.42-0.73)    6      (0.12-0.31)    (0.29-0.56)    3
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

OS, overall survival; CI, confidence interval; EFS, event-free survival.

![*MAPKBP1*^high^ is associated with unfavourable treatment\
(A) EFS and (B) OS in the entire cohort of 157 CN-AML cases.](oncotarget-06-8144-g002){#F2}

Associations of *MAPKBP1* expression with clinical outcome in ELN genetic groups {#s2_4}
--------------------------------------------------------------------------------

We analysed the associations between *MAPKBP1* expression and outcome separately within the ELN favourable and Intermediate-I genetic groups. Within the ELN favourable group (n = 59), there was no significant difference in EFS (Figure [3A](#F3){ref-type="fig"}, *P* = 0.0899) and OS (Figure [3B](#F3){ref-type="fig"}, *P* = 0.1561) between *MAPKBP1*^high^ group and *MAPKBP1*^low^group. However, *MAPKBP1*^high^ group tended to have shorter EFS and OS than *MAPKBP1*^low^ group. In the ELN Intermediate-I group (n = 122), *MAPKBP1*^high^ group had a shorter EFS (Figure [3C](#F3){ref-type="fig"}, *P* = 0.0073) and shorter OS (Figure [3D](#F3){ref-type="fig"}, *P* = 0.0086) than *MAPKBP1*^low^ group. Median OS and EFS of different expressing divisions also showed a significant difference. (Table [2](#T2){ref-type="table"}).

![Associations of *MAPKBP1* expression with clinical outcome in ELN genetic groups\
(A) EFS and (B) OS of CN-AML patients in the ELN favourably genetic group. (C) EFS and (D) OS of CN-AML patients in the ELN intermediate-I genetic group.](oncotarget-06-8144-g003){#F3}

*MAPKBP1* expression is associated with shorter EFS and OS in multivariable analyses {#s2_5}
------------------------------------------------------------------------------------

After adjusting for the impact of several known risk factors, we performed multivariable analyses to determine the prognostic significance of *MAPKBP1* expression. In the multivariable model of EFS, *MAPKBP1*^high^ group had a shorter EFS (*P* = 0.009, Table [3](#T3){ref-type="table"}). The other factors associated with shorter EFS were the *NPM1* wild type and *FLT3-ITD* genotypes. In a multivariable model for OS, *MAPKBP1*^high^ group had a shorter OS (*P* = 0.01, Table [3](#T3){ref-type="table"}). The other factors associated with shorter OS were the *NPM1* wild type and *FLT3-ITD* genotypes.

###### Multivariable analysis with EFS and OS for the CN-AML patients

  Variable                          OS, n=157          EFS, n=157                      
  --------------------------------- ------------------ ------------ ------------------ -------
  MAPKBP1 expression, high vs low   1.87 (1.20-2.91)   0.006        1.87 (1.23-2.84)   0.003
  Age, per 10-y increase            1.17 (1.00-1.35)   0.036        1.08 (0.95-1.24)   0.251
  Sex, male vs female               0.82 (0.54-1.24)   0.35         0.99 (0.67-1.46)   0.962
  NPM1, mutated vs wild type        0.5 (0.31-0.79)    0.003        0.52 (0.34-0.81)   0.004
  FLT3-ITD, mutated vs wild type    1.77 (1.10-2.85)   0.018        1.63 (1.04-2.55)   0.033
  CEBPA, mutated vs wild type       0.64 (0.34-1.22)   0.174        0.71 (0.39-1.28)   0.258

CN-AML indicates cytogenetically normal acute myeloid leukemia; RFS, relapse-free survival; OS, overall survival; EFS, event-free survival; HR, hazard ratio; CI, confidence interval; and ITD, internal tandem duplication;

Validation in a large and independent cohort of CN-AML samples {#s2_6}
--------------------------------------------------------------

We studied an independent cohort of 162 previously untreated CN-AML patients. In the validating cohort, patients with M1 and M6 disease were more likely to have *MAPKBP1*^high^ in the FAB subtype (*P* = 0.001, *P* = 0.00284, respectively).We also found that *MAPKBP1*^high^ patients with CN-AML were more likely to have a higher expression of *ERG1*, *MN1*, *WT1*, *DNMT3B* and *TCF4* (*P* \< 0.001, *P* = 0.028, *P* \< 0.001, *P* \< 0.001, and *P* \< 0.001, respectively) and low LEF1 (*P* \< 0.001) compared with *MAPKBP1*^low^ patients ([supplemental Table S1](#SD1){ref-type="supplementary-material"}). In addition, *MAPKBP1*^high^ patients showed a significantly shorter OS (n=81 vs n=81, *P* = 0.00172; [supplemental Figure 1](#SD1){ref-type="supplementary-material"}) than *MAPKBP1*^low^ patients in the validating cohort.

Genome-wide gene-expression profiles associated with *MAPKBP1* expression {#s2_7}
-------------------------------------------------------------------------

In order to further evaluate the role of *MAPKBP1* in CN-AML, we derived *MAPKBP1*-associated gene-expression profiles using a microarray analysis. We identified 571 up-regulated genes and 757 down-regulated genes that were significantly associated with *MAPKBP1*^high^ ([supplemental Table S2](#SD1){ref-type="supplementary-material"}). The up-regulated genes included some of those previously found to be involved in AML, including *CDK6* and *CCND2* that encode a cyclin kinase, *MYCN*, *MYB*, *WT1*, members of the *HOX* gene family (*HOXB2, HOXB3, HOXB8, HOXA3, HOXA4*, and *HOXA5*) that encode transcription factor proteins, and c-kit that encodes a tyrosine kinase. *ERG*, an independent unfavourable prognostic factor in CN-AML, was also up-regulated. *MiR-155* host gene up-regulation in *MAPKBP1*^high^ CN-AML was unexpected as this microRNA was previously found to function as an oncogene in CN-AML \[[@R21]\]. The down-regulated genes included those involved with both normal differentiation gene of monocyte/macrophage including *CEBPB* and immune function including *CD14*, *TLR4*, and *TLR8* (Figure [4](#F4){ref-type="fig"}). These provided further support for the correlation described above.

![Genes and microRNAs associated with *MAPKBP1* expression\
(A) expression heatmap of associated genes (B) the list of associated genes. (C) expression heatmap of associated microRNAs (D) the list of associated microRNAs.](oncotarget-06-8144-g004){#F4}

The *MAPKBP1*-associated cell signalling pathways were evaluated by MSigDB \[[@R30]\] in order to assess the biological features of the expression profile of *MAPKBP1* (Table [4](#T4){ref-type="table"}). Signalling pathways involved in apoptosis, antigen processing and natural killer cells mediated cytotoxicity were down-regulated (*P* = 0.024, *P* \< 0.001, and *P* = 0.007, respectively). These findings were consistent with the above noted dysregulated genes involved in the development of CN-AML.

###### Cell signalling pathways associated with *MAPKBP1* expression levels

  Pathway name                                        According to high expression of *MAPKBP1*   
  --------------------------------------------------- ------------------------------------------- ---------
  KEGG_CHEMOKINE_SIGNALING_PATHWAY                    Down                                        0.044
  KEGG_UBIQUITIN_MEDIATED_PROTEOLYSIS                 Up                                          0.021
  KEGG_APOPTOSIS                                      Down                                        0.024
  KEGG_ANTIGEN_PROCESSING_AND_PRESENTATION            Down                                        \<0.001
  KEGG_NATURAL_KILLER_CELL_MEDIATED_CYTOTOXICITY      Down                                        0.007
  KEGG_FC_GAMMA_R\_MEDIATED_PHAGOCYTOSIS              Down                                        0.017
  KEGG_INTESTINAL_IMMUNE_NETWORK_FOR_IGA_PRODUCTION   Down                                        \<0.001
  KEGG_CHRONIC_MYELOID_LEUKEMIA                       Up                                          0.033

Genome-wide *microRNA* profiles associated with *MAPKBP1* expression {#s2_8}
--------------------------------------------------------------------

An analysis of microRNA genome-wide profiles revealed that 78 microRNAs were significantly associated with *MAPKBP1* expression (*P* \< 0.05) ([supplemental Table S3](#SD1){ref-type="supplementary-material"}). *MAPKBP1*^high^ was associated with *miR-155, miR-146a, miR-92a-1, miR-126, miR-133a, miR-25*, and *miR-130a* up-regulation. Up-regulation of *miR-155* was consistent with the gene-expression profiles. *MiR-146a* lost in myelodysplastic syndrome (MDS) with 5q- and related with down-regulation of immune-response pathway \[[@R31], [@R32]\]. *MiR-92a-1* arouses erythroleukemia through *p53* down-regulation \[[@R33]\]. *MiR-126* promotes survival and inhibits apoptosis of AML cells \[[@R34]\]. *MiR-133a* was up-regulated in CN-AML with *IDH2* codon R172K \[[@R35]\]. *MiR-25* increases somatic cells into induced pluripotent stem cells \[[@R36]\]. *MiR-130a* associated with high expression of *WT1* \[[@R32]\]. Notably *miR-148a* and *miR-193a* were down-regulated. *miR-148a* has recently been shown to target *DNMT3B* \[[@R37]\], the expression of which is an independent unfavourable prognostic factor in older CN-AML patients \[[@R18]\], and it is also associated with *ERG* up-regulation \[[@R16]\]. This was consistent with the gene-expression profiles. We previously found that *miR-193a* targeted *c-kit*, leading to higher expression of this gene, which is also consistent with the observed gene-expression profiles (Figure [4](#F4){ref-type="fig"}) \[[@R38], [@R39]\].

Genome-wide methylation profiling associated with *MAPKBP1* expression {#s2_9}
----------------------------------------------------------------------

The control of gene expression by DNA methylation has been suggested to play a pivotal role in determining the biological behaviour of cells, and the DNA methylation classifier could predict clinical outcome in AML patients \[[@R40], [@R41]\]. We therefore assessed whether *MAPKBP1*^high^ and *MAPKBP1*^low^ CN-AML showed different DNA methylation patterns overall, within important cell signalling pathways and individual genes. However, we found no significant differences in DNA methylation with respect to *MAPKBP1* expression in any of these analyses ([Supplementary Figure 2, 3](#SD1){ref-type="supplementary-material"}, DNA methylation patterns of cell signalling pathways\' data not shown).

DISCUSSION {#s3}
==========

Our results are of particular interest because a recent paper showed that *MAPKBP1* was an important constitutive activator of *NF-κB* signalling pathway which was required for self-renewal of normal hematopoietic and leukemic stem cells \[[@R42], [@R43]\]. Leukemogenic fusion genes and gene mutations can induce *NF-κB* cell signalling pathway in AML \[[@R44]\], and small-molecule *NF-κB* pathway inhibitors are cytotoxic for AML blasts \[[@R45]\], and the *SP1/NF-κB* transactivation complex mediated SPARC expression, contributing to leukemogenesis in CN-AML \[[@R26]\]. These findings suggest that expression of *MAPKBP1* may be a prognostic factor in patients with CN-AML.

Our study is the first report on the prognostic relevance of *MAPKBP1* expression in CN-AML, and demonstrates that *MAPKBP1*high is associated with shorter EFS and OS in CN-AML.

*MAPKBP1* was up-regulated in CN-AML compared with normal BM. We found that patients with *MAPKBP1*high were significantly more classified in the M1 FAB subgroups, suggesting that the leukemic cells of the *MAPKBP1*^high^ patients derive from immature cells. We also found that *MAPKBP1*^high^ was associated with the presence of *FLT3-ITD,* higher *ERG, WT1, DNMT3b*, *TCF4* expression, and lower *LEF1* expression, all of which are unfavourable molecular characteristics in CN-AML. Furthermore, the association of *MAPKBP1*^high^ with shorter EFS and OS was confirmed in multivariable analyses adjusting for other known clinical and molecular prognosticators in CN-AML. *MAPKBP1*^high^ was associated with wild type *NPM1* and *FLT3-ITD*, both of which are unfavourable molecular characteristics in CN-AML. These results indicated that *MAPKBP1*^high^ was a surrogate marker for other unfavourably genetic lesions such as the *FLT3-ITD*. Our results suggest that the prognostic impact of *MAPKBP1* expression was most pronounced in the ELN intermediate-I genetic group, and thus *MAPKBP1* expression may be used to further refine risk stratification for these patients.

The mechanisms underlying the association between *MAPKBP1*^high^ and unfavourable treatment outcomes are unclear. In our present study, we analysed gene and microRNA expression, and DNA methylation profiles to identify biological pathways that are associated with *MAPKBP1* expression in CN-AML. Gene sets related to cell proliferation and cell cycle regulation were up-regulated in the CN-AML cells of *MAPKBP1*^high^ patients, and gene sets related to apoptosis were down-regulated. Furthermore, antigen processing and natural killer cell-mediated cytotoxicity, which can lead to immune escape, were down-regulated in CN-AML with *MAPKBP1*high \[[@R46], [@R47]\]. These changes might contribute to an unfavourable outcome.

The *MAPKBP1*-associated microRNA profile was also noteworthy, as it included nine important *microRNAs* that were differentially expressed in *MAPKBP1*^high^ CN-AML. The up-regulation of *miR-155* was associated with an unfavourable clinical outcome independently in CN-AML, *miR-130a* associated with high expression of *WT1*, and the down-regulation of *miR-148a* and *miR-193a* contributed AML leukemogenesis. However, we found no significant association between *MAPKBP1* expression levels and overall methylation, or the methylation of tumour suppressor genes, or genes involved in important cell signalling pathways.

In summary, our study is the first to provide evidence that *MAPKBP1*^high^ is associated with unfavourable outcomes in CN-AML patients, even after adjusting for most of known molecular risk factors. Because the gene is widely expressed at a high level in CN-AML compared with normal BM, *MAPKBP1* expression can be easily measured. Further qPCR confirmation of microarray expression data could validate these results and made them more reliable. This may therefore be a valuable new marker for risk stratification of CN-AML patients. Moreover, our gene/microRNA expression data from a large cohort of primary CN-AML patients provides insights into the biological changes associated with varying *MAPKBP1* expression levels in CN-AML, and might help direct new therapeutic strategies for CN-AML patients.

METHODS {#s4}
=======

Patients and treatment {#s4_1}
----------------------

One hundred and fifty-seven patients with previously untreated CN-AML (median age, 50 years; range, 16--77 years) were studied, all of whom were received uniform therapeutic treatment based on study protocols of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) between 1990 and 2008 (available at <http://www.hovon.nl>). The details of therapeutic protocol were shown in [supplementary Figure 4](#SD1){ref-type="supplementary-material"} \[[@R48]\]. One hundred thirty patients (83%) were aged \<60 years (younger patients) and 27 patients (17%) were ≥ 60 years (older patients). The diagnosis of a normal karyotype was based on conventional cytogenetic examination of at least 20 metaphases from BM. Patients were assessed for *NPM1, CEBPA, N-RAS, K-RAS, IDH1*, and *IDH2* mutations, *FLT3-ITD*, and tyrosine kinase domain mutations (*FLT3-TKD* \[D835\]). Clinical, cytogenetic and molecular information as well as the gene expression profiles of all primary AML cases could be publicly downloaded at the Gene Expression Omnibus ([www.ncbi.nlm.nih.gov/geo](http://www.ncbi.nlm.nih.gov/geo), accession number *GSE6891*) \[[@R48]\]. This research was approved by the institutional review boards at Weill Cornell Medical College and Erasmus University Medical Center, and written donor informed consent was obtained in accordance with the Declaration of Helsinki \[[@R41]\]. Another independent validation cohort of 162 CN-AML patients also received uniform therapeutic treatment provided by the multicenter AMLCG-1999 trial was used to validate our findings. These patients received intensive double induction and consolidation chemotherapy. Gene expression data are publicly available (<http://www.ncbi.nlm.nih.gov/geo/>, accession number *GSE12417*) \[[@R49]\]. The AMLCG-1999 clinical trials were approved by the local institutional review boards, and informed consent from all patients was obtained in accordance with the Declaration of Helsinki \[[@R49]\].

Microarray analyses {#s4_2}
-------------------

Gene expression and methylation data have been previously published (accession number *GSE1159* \[[@R29]\], *GSE6891* \[[@R48]\] and *GSE12417* \[[@R49]\] for expression, *GSE18700* \[[@R41]\] for methylation). Briefly, gene expression and methylation data were obtained using Affymetrix Human Genome 133 plus 2.0 Gene Chips, Human Genome U133A and HELP methylation arrays \[[@R41]\]. All the design and quality control for microarray experiment were according to the standard Affymetrix protocols. Expression data of microRNA were carried out from The Cancer Genome Atlas (TCGA) obtained by whole-genome high-throughput sequencing, which provided 79 CN-AML patients \[[@R50]\]. Patients with *MAPKBP1* expression values above the median of all patients were classified as having *MAPKBP1*^high^, and the others were considered to have *MAPKBP1*^low^. *ERG, BAALC, LEF1, MN1, EVI1, WT1, DNMT3B*, and *TCF4* expression levels were also determined from the microarray data.

Statistical analyses {#s4_3}
--------------------

The time from date of diagnosis to removal from study due to absence of complete remission, relapse or death defined EFS, and the time from date of diagnosis to death due to any cause defined OS. Firstly, we subdivided 157 CN-AML patients into four quartiles (Q1: \<25%, Q2: 25\~50%, Q3: 50\~75%, Q4: \>75%) based on *MAPKBP1* expression value to determine the best classification method of this group. No significant difference was observed between Q1 and Q2 (Q12, *P* = 0.97), and the same result was also observed between Q3 and Q4 (Q34, *P* = 0.335). However, patients in Q2 and Q3 (Q23, *P* = 0.047) had significant differences ([supplementary Figure 5](#SD1){ref-type="supplementary-material"}). Secondly, median values of *MAPKBP1* expression were calculated in order to divide patients into high and low expression groups. The Kaplan-Meier method was then used to estimate the association between *MAPKBP1* expression and the EFS and OS, which were further validated using a log-rank test. To investigate the associations between *MAPKBP1* expression levels and clinical, molecular characteristics, the Fisher exact and Wilcoxon rank-sum tests were used in the hypothesis testing for categorical and continuous variables, respectively. In addition, multivariable Cox proportional hazards models were used to study how *MAPKBP1* expression levels associated with EFS and OS in the presence of other known risk factors. According to the two groups divided by *MAPKBP1* expression levels, Student\'s *t*-test and multiple hypothesis correction (False Discovery Rate, FDR) was used to identify differences in gene-microRNA expression and DNA methylation profiles. The statistical cutoff values were an fold-change (FC) \>= 1.5 and an adjusted *P*-value \<= 0.05. All analyses were performed using the R 3.1.1 software packages.
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